Info
🌱 來自: Metastatic Colon Cancer
PRIME
- Design: Phase III, randomized, multicenter trial
- Number of patients: 1183
- Patients characteristics: previously untreated wild-type KRAS metastatic colorectal cancer
- Agent: panitumumab-FOLFOX4 (arm 1) or FOLFOX4 alone (arm 2)
- Treatment line: first-line
- Trial Name/NCT Number: NCT00364013
| Group | Progression-free survival (PFS) | Overall survival (OS) | Response rate (RR) |
|---|---|---|---|
| Arm 1 | 10.0 months | 23.9 months | Higher objective response |
| Arm 2 | 8.6 months | 19.7 months | not reported |
-
Other findings:
- An exploratory analysis of updated survival showed significant improvement in OS for arm 1
- Adverse event profile consistent with primary analysis
-
Summary: The PRIME study demonstrated that panitumumab-FOLFOX4 significantly improved PFS and OS in patients with previously untreated wild-type KRAS metastatic colorectal cancer, with a higher objective response rate. These data